Curaleaf (CURLF) has been one of many huge beneficiaries of the most recent hashish fervor. CURLF inventory has climbed roughly 80% yr to this point and up greater than 230% over the previous three months as merchants worth in a potential federal rescheduling tailwind and the corporate’s regular push to stabilize operations.
Curaleaf constantly stands out for traders monitoring multi-state operators (MSOs). Its expansive U.S. retail footprint, broad product lineup, and rising worldwide presence place it as a high decide when coverage dangers start to ease and speculative capital flows again into the sector.
Valued at $1.7 billion by market cap, Curaleaf runs one of many largest U.S. dispensary networks and sells a broad array of consumer-facing hashish merchandise, flower, vapes, edibles and hemp-derived drinks. The corporate has been working by what administration calls a “home stabilization” plan: trimming overhead, focusing shops on profitability, and leaning into higher-margin branded merchandise. That mixture of scale and product attain is precisely what merchants wish to personal if federal coverage strikes to scale back hashish’ authorized friction.
On paper, CURLF’s valuation seems enticing. Its worth/gross sales (P/S) ratio of 1.5 is notably under the sector median of three.5, suggesting a extra reasonably priced inventory in comparison with its friends.
Curaleaf isn’t simply driving headlines. It’s opening shops and increasing distribution for branded merchandise. The corporate operates roughly 150+ U.S. dispensaries and has been rolling out shopper merchandise into non-dispensary channels, notably putting hemp-derived seltzers and different objects into mainstream retail.
These distribution strikes check whether or not Curaleaf can construct CPG-like attain past the regulated dispensary channel, a possible multiplier if federal guidelines loosen. Internationally, Curaleaf is consolidating possession in key markets and getting ready for scaled launches overseas, which might add higher-margin income over time.
Earlier this month, Curaleaf reported its Q2 earnings, which got here above expectations and confirmed indicators of stabilization, but additionally reminded traders that the enterprise isn’t out of the woods. Q2 income got here in at $314.5 million, down about 8% year-over-year, however gross margin expanded to roughly 49% and adjusted EBITDA landed round $65–66 million on a 21% margin. Curaleaf has reported a rise in worldwide hashish gross sales, with a 74% rise year-over-year (YOY) in Q1 2025, highlighting strong progress in worldwide markets like Germany and the UK.